Vincerx Pharma
Stock Forecast, Prediction & Price Target
Vincerx Pharma Financial Estimates
Vincerx Pharma Revenue Estimates
Vincerx Pharma EBITDA Estimates
Vincerx Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $17.56M Low: $17.56M High: $17.56M avg. 0% | Avg: $870K Low: $870K High: $870K avg. -95.04% | Avg: $7.55M Low: $7.55M High: $7.55M avg. 767.81% | |
Net Income
% change YoY
| $-15.60M N/A | $-57.16M -266.22% | $-40.15M 29.74% | Avg: $-33.76M Low: $-22.35M High: $-10.22M avg. 15.91% | Avg: $-54M Low: $-21.93M High: $-21.93M avg. -59.92% | Avg: $-18.10M Low: $-18.10M High: $-18.10M avg. 66.48% | |
EBITDA
% change YoY
| $-86.01M N/A | $-74.93M 12.87% | $-42.60M 43.14% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | |
EPS
% change YoY
| -$0.91 N/A | -$2.72 -198.90% | -$1.89 30.51% | Avg: -$0.76 Low: -$1.05 High: -$0.48 avg. 59.61% | Avg: -$1.03 Low: -$1.03 High: -$1.03 avg. -34.93% | Avg: -$0.85 Low: -$0.85 High: -$0.85 avg. 17.47% | |
Operating Expenses
% change YoY
| $62.65M N/A | $71.10M 13.48% | $42.60M -40.07% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | |
FAQ
What is Vincerx Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 7.49% in 2025-2027.
We have gathered data from 2 analysts. Their low estimate is -22.35M, average is -33.76M and high is -10.22M.
What is Vincerx Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 224.25% in 2025-2027.
We have gathered data from 3 analysts. Their low revenue estimate is $17.56M, average is $17.56M and high is $17.56M.
What is Vincerx Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 14.05% in 2025-2027.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.05, average is -$0.76 and high is $-0.48.
What is the best performing analyst?
In the last twelve months analysts have been covering Vincerx Pharma stock. The most successful analyst is Matthew Barcus whose win rate is 100%. He has correctly predicted 1/1 price targets.